Program
QL2106
A development code. Also written as “QL2106 injection”.
Its studies are mostly in Psoriasis, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 21 open or running | phase 3since Mar 30, 2026 | Nov 14, 2025 | Dec 30, 2027phase 3 · NCT07511647 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2025First study: phase 1 study in Healthy ParticipantsFirst studyNCT07479576 · 190 enrolled · China
- Mar 30, 2026Phase 3 study in Plaque PsoriasisPhase 3 reachedNCT07511647 · 318 enrolled · China
Ahead
- Dec 30, 2027Primary completion: phase 3 study in Plaque PsoriasisNCT07511647
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07511647Plaque Psoriasis · China | 3 | Active, not recruiting | Dec 30, 2027 | 318 |
| NCT07479576Healthy Participants · China | 1 | Completed | Apr 23, 2026 | 190 |
How it is read
Names in the registry
- “QL2106 injection”, 1 entry
- “QL2106”, 1 entry
Codes read as this program: QL2106.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.